Target intelligence / Profile preview

Niemann-Pick C1-like intracellular cholesterol transporter 1 (NPC1L1)

Target
NPC1L1
Molecular classification
Transporter, Membrane protein
01

Overview

Niemann-Pick C1-like intracellular cholesterol transporter 1 is a multi-pass membrane protein primarily expressed on epithelial cells of the gastrointestinal tract and hepatocytes. It plays a critical role in mediating the uptake and transport of dietary and biliary free cholesterol into enterocytes through vesicular endocytosis, thus regulating whole-body lipid homeostasis. The protein also facilitates plant sterol absorption at lower rates than for cholesterol, as well as alpha-tocopherol transport. It is directly inhibited by ezetimibe, a clinically approved drug for lowering plasma LDL-cholesterol by reducing intestinal absorption. Polymorphic variations in its gene are associated with differences in plasma lipid levels and coronary heart disease risk. Beyond cardiovascular implications, it has been implicated as an accessory receptor for hepatitis C virus entry into cells. The transporter belongs to the patched family of proteins.

Other names
NPC1L1Niemann-Pick C1-like protein 1NPC1-like intracellular cholesterol transporter 1NPC1-like 1
02

Mechanism of action

Inhibition of intestinal and hepatic cholesterol absorption by blocking the function of NPC1L1, leading to reduced blood LDL-cholesterol levels; ezetimibe binds directly to this protein to exert its effect

03

Biological functions

Cholesterol absorption in the intestine and hepatocytesRegulation of lipid metabolismUptake of free cholesterol into cells via vesicular endocytosisTransport of alpha-tocopherol (vitamin E)Plant sterol absorption (e.g., sitosterol, at lower rates than cholesterol)
04

Disease associations

Cardiovascular disease (through effects on LDL-C and total cholesterol levels)Coronary heart disease risk modulationHypercholesterolemia/hyperlipidemia management target
05

Safety considerations

Potential association with altered cancer risk was hypothesized but not confirmed in meta-analysis for ezetimibe use targeting this molecule; no increased cancer risk found with treatment.Genetic polymorphisms may affect drug efficacy or predispose individuals to altered lipid profiles or cardiovascular risks.
06

Interacting drugs

Ezetimibe (direct inhibitor)
07

Biomarkers

Plasma total cholesterol levelLow-density lipoprotein cholesterol (LDL-C) level

Beyond the preview

Go deeper on Niemann-Pick C1-like intracellular cholesterol transporter 1 (NPC1L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niemann-Pick C1-like intracellular cholesterol transporter 1 (NPC1L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call